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Colorectal Cancer:
Colorectal cancer commonly called colon cancer or bowel cancer is
the 4th most frequent cause of cancer in the United States and it is
the 2nd leading cause of cancer-related deaths in the United States.

Stages of Colorectal Cancer
Stage 0 -- Cancer is only in the innermost lining of the colon or rectum.
Stage I -- Cancer has not spread beyond the inner wall of the colon or
rectum.
Stage II -- Cancer has spread into the muscle layer of the colon or rectum.
Stage III -- Cancer has spread to one or more lymph nodes in the area.
Stage IV -- Cancer has spread to other parts of the body, such as the liver,
lung, or bones.

Colorectal Cancer
stage

Chance of cure

I

80-95%

II

55-80%

III

40%

IV

10%

Local vs Metastatic Colon Cancer
Colon
Cancer
Metastatic:
The cancer has spread
through the blood and
lymph nodes to other parts
of the body. Major
treatment is
chemotherapy.

Local:
Those that remain in the
intestinal lining and can be
easily removed using
surgery

OUR
APPROACH

Using T-Cell
Based
Immunotherapy
to Target
Metastatic Colon
Cancer

Guanylyl cyclase C is a transmembrane receptor with high
expression in intestinal epithelial cells

Guanylyl cyclase C, a member of guanylyl cyclase family of receptors,
is the receptor for two endogenous ligands guanylin and uroguanylin
and for the exogenous ligand heat-stable enterotoxin, ST. It’s main
function is fluid hemostasis and electrolyte homostasis. As a mucosa
specific protein, which is so highly restricted in its expression, GCC
can be utilized to detect metastases in non-intestinal tissues.

DIAGRAM OF A T CELL RECEPTOR



T cells are activated by
binding of the T cell
receptor (TCR) to a
peptide-major
histocompatibility
complex (MHC) complex
(pMHC) expressed on the
surface of antigen
presenting cell.
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When T cell receptor is engaged:
Signals are transmitted
T cells becomes activated
T cell expresses activation markers
T cell produces Immune factors
T cell proliferates
T cell kills target cells

Adoptive T Cell Transfer
•

Process that involves:

1)

Removing lymphocytes
(in this case the T cells)
from the patient
Tranducing the TCR of
the T cells
Grow them to large
numbers
Return Cells to the
Patient

2)
3)
4)

Project:
Cloning GCC specific TCR

Viral Vector Vaccines

Adenovirus
Cancer antigen: GCC-Ad
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T-hybridoma Technology Diagram
Antigen

Fusion Partner

T Cells from
Spleen
Fuse in polyethylene
glycol
Select and grow hybrid
cells using HAT media

Test for antigen specific
positive T cells

Propagate clones

T-Hybridoma Technology
Explanation
 The picture is showing a mouse being immunized with a viral vector vaccine. Once the
mouse has mounted an immune response , the spleen is harvested and the splenocytes
(site of T cells) are isolated.
 These isolated T cells are then fused with thymoma cells that are being grown in a culture
by using polyethelene glycol (PEG). The fusion product is called T-hybridoma.
 HAT is then added to kill non-fused cells and then selection of growing T-hybridoma is
done at a later date.
 Test of antigen specific T cells are then done using MUG assay.

Procedure
Mice were given the GCCAd5 vaccine

Some splenocytes were
collected in 3 flasks for 1
wk, 2wk and 3wk
stimulation with GCCpeptide and RhIL-2.

At D14, Spleen from
immunized mice
harvested and cells
collected.
Fusion of
both cells in
1:1 ratio
using PEG

HAT added at
D1 and D7 to
kill non-fused
cells

At D12, growing
t-hybridomas
transferred to 24wells.

Immortal cancer
(BWZ/CD8) cells
grown in medium

AT D16, MUG assay
done to select GCC
T-hybridoma using
DMSO as a control

Results
 Growing T-hybridoma were obtained but none that

were GCC specific.
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Summary of project


T hybridoma technology has proven to be an effective way to identify antigen specific TCRs.



However in order to increase fusion efficiency for tests, critical measures have to be revised: During
the fusion reaction, maintaining the temperature at 37°C is very important for the membrane events
that occur during and immediately after the PEG mediated fusion event. Because of the small volume,
the cells can rapidly come down to room temperature.

 In addition, the thymoma cells could also be tested to see if they are still potent for the
method.

Future Directions
 Clone out the T-cell receptor of GCC specific CD8 T

Cells and test their affinity.
 Give mice colon cancer cell lines-CT26 modified to
express GCC and then treat them with GCC-specific
TCR transduced CD8 T Cells.
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